Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.

Low TB patients also showed a trend towards longer PFS (6.80 vs. 5.47 months, p = 0.276, Figure S6A).

also in 53,322 other papers

Consistent with the primary analysis, patients with low TB exhibited significantly longer PFS and a borderline significant improvement in OS compared to those with high TB in the chemoimmunotherapy arm, whereas no significant survival differences were observed in the chemotherapy arm (Figure S3).

also in 11,409 other papers